These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 33314309)

  • 1. Weight gain post-heart transplantation is associated with an increased risk for allograft vasculopathy and rejection.
    Ram E; Klempfner R; Peled A; Kassif Y; Sternik L; Lavee J; Peled Y
    Clin Transplant; 2021 Mar; 35(3):e14187. PubMed ID: 33314309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up.
    Peled Y; Lavee J; Raichlin E; Katz M; Arad M; Kassif Y; Peled A; Asher E; Elian D; Har-Zahav Y; Shlomo N; Freimark D; Goldenberg I; Klempfner R
    Clin Transplant; 2017 Dec; 31(12):. PubMed ID: 28990263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
    ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac allograft vasculopathy in pediatric heart transplant recipients does early-onset portend a worse prognosis?
    Khoury M; Conway J; Gossett JG; Edens E; Soto S; Cantor R; Koehl D; Barnes A; Exil V; Glass L; Kirklin JK; Zuckerman WA
    J Heart Lung Transplant; 2022 May; 41(5):578-588. PubMed ID: 35172937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of the first post-transplant biopsy for predicting long-term cardiac allograft vasculopathy (CAV) and graft failure in heart transplant patients.
    Labarrere CA; Woods JR; Hardin JW; Campana GL; Ortiz MA; Jaeger BR; Baldridge LA; Pitts DE; Kirlin PC
    PLoS One; 2012; 7(4):e36100. PubMed ID: 22558345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of the IFN-gamma-inducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: association with cardiac allograft vasculopathy and acute rejection.
    Zhao DX; Hu Y; Miller GG; Luster AD; Mitchell RN; Libby P
    J Immunol; 2002 Aug; 169(3):1556-60. PubMed ID: 12133984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of Low Serum Magnesium to Mortality and Cardiac Allograft Vasculopathy Following Heart Transplantation.
    Ram E; Lavee J; Shechter M; Kogan A; Maor E; Asher E; Freimark D; Klempfner R; Peled Y
    Am J Cardiol; 2020 May; 125(10):1517-1523. PubMed ID: 32238278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity and dyslipidemia predict cardiac allograft vasculopathy and graft loss in children and adolescents post-heart transplant: A PHTS multi-institutional analysis.
    Bogle C; Cantor R; Koehl D; Lochridge J; Kirklin JK; Barnes A; Wallis G; Amdani S; Ameduri R; Pahl E; Simpson KE; Blume ED
    Pediatr Transplant; 2022 Aug; 26(5):e14244. PubMed ID: 35122464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of acidic fibroblast growth factor and untreated low grade rejection with cardiac allograft vasculopathy.
    Zhao XM; Citrin BS; Miller GG; Frist WH; Merrill WH; Fischell TA; Atkinson JB; Yeoh TK
    Transplantation; 1995 Apr; 59(7):1005-10. PubMed ID: 7535956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation.
    Bergmark BA; Zelniker TA; Kim M; Mehra MR; Stewart GC; Page DS; Woodcome EL; Givertz MM
    Clin Transplant; 2021 Oct; 35(10):e14424. PubMed ID: 34254366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
    Asimacopoulos EP; Garbern JC; Gauvreau K; Blume ED; Daly KP; Singh TP
    Transplantation; 2020 Jan; 104(1):e31-e37. PubMed ID: 31568274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction model for cardiac allograft vasculopathy: Comparison of three multivariable methods.
    Kransdorf EP; Loghmanpour NA; Kanwar MK; Temkit MH; Stehlik J
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography.
    Zanchin C; Yamaji K; Rogge C; Lesche D; Zanchin T; Ueki Y; Windecker S; Mohacsi P; Räber L; Sigurdardottir V
    PLoS One; 2018; 13(8):e0202950. PubMed ID: 30148864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-immune risk predictors of cardiac allograft vasculopathy: Results from the U.S. organ procurement and transplantation network.
    Fluschnik N; Geelhoed B; Becher PM; Schrage B; Brunner FJ; Knappe D; Bernhardt AM; Blankenberg S; Kobashigawa J; Reichenspurner H; Schnabel RB; Magnussen C
    Int J Cardiol; 2021 May; 331():57-62. PubMed ID: 33571561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival, graft function, and incidence of allograft vasculopathy in heart transplant patients receiving adverse risk profile donor hearts.
    Berg K; Clemmensen TS; Tram EM; Koefoed-Nielsen P; Ilkjaer LB; Poulsen SH; Eiskjaer H
    Clin Transplant; 2018 Aug; 32(8):e13343. PubMed ID: 29974979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 21 (IL-21) regulates chronic allograft vasculopathy (CAV) in murine heart allograft rejection.
    Khattar M; Baum CE; Schroder P; Breidenbach JD; Haller ST; Chen W; Stepkowski S
    PLoS One; 2019; 14(11):e0225624. PubMed ID: 31756235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation.
    Ram E; Lavee J; Tenenbaum A; Klempfner R; Fisman EZ; Maor E; Ovdat T; Amunts S; Sternik L; Peled Y
    Cardiovasc Diabetol; 2019 Sep; 18(1):118. PubMed ID: 31526382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged corrected QT interval in the donor heart: Is there a risk?
    Leong D; Aintablian T; Kittleson M; Olymbios M; Patel J; Chang DH; Kobashigawa J
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28470875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Outcomes of Cardiac Allograft Vasculopathy Over 30 Years Following Heart Transplantation.
    Tremblay-Gravel M; Racine N; de Denus S; Ducharme A; Pelletier GB; Giraldeau G; Liszkowski M; Parent MC; Carrier M; Fortier A; White M
    JACC Heart Fail; 2017 Dec; 5(12):891-901. PubMed ID: 29191295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the development of cardiac allograft vasculopathy.
    Seki A; Fishbein MC
    Cardiovasc Pathol; 2014; 23(5):253-60. PubMed ID: 24972526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.